Inflammaging: A Skeptical Look at What Chronic Inflammation Really Tells Us

Last reviewed: May 2026

Walk into any longevity-supplement website and you will hit “inflammation” within the first scroll. Chronic inflammation is the villain. Reduce it and you reduce your biological age. Research-protocol patterns describe this turmeric blend, or this curcumin nano-formulation, or this proprietary mushroom complex. The framing is consistent enough that it has its own micro-economy.

So is it true? Mostly yes, with caveats that get lost in the marketing. The underlying science is real. The wellness-industry application of that science is patchier than the marketing implies. This is the careful version.

Where the term came from

Claudio Franceschi and colleagues coined “inflamm-aging” in a 2000 Annals of the NY Academy of Sciences paper. The hyphen has since been dropped. The concept: aging is accompanied by a chronic, low-grade, sterile (not infection-driven) inflammatory state, characterised by elevated baseline pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) without an active acute infection. Franceschi argued this was an evolutionarily recent phenomenon: the immune system was selected to handle acute threats, not to manage decades of cellular accumulation, and the chronic background activation we see in older adults is in some sense a side effect of the system running on its default settings for too long.

Twenty-five years on, the concept has held up. Ferrucci and Fabbri’s 2018 Nature Reviews Cardiology paper updated the framework with the data that has accumulated since: chronic low-grade inflammation is not just a marker of aging, it is a causal contributor to multiple age-related diseases including cardiovascular disease, type 2 diabetes, cognitive decline, and frailty. The Furman et al 2019 Nature Medicine paper on chronic inflammation in disease etiology covered the cross-disease story comprehensively.

What is actually causing the chronic inflammation

This is where the wellness conversation tends to oversimplify. The drivers of inflammaging are multiple and interactive. The major contributors:

1. Senescent cell accumulation. Cells that have stopped dividing but resist apoptosis secrete a cocktail of inflammatory molecules called the senescence-associated secretory phenotype (SASP). The SASP is one of the cleanest mechanistic stories in inflammaging.
2. Mitochondrial dysfunction. Damaged mitochondria release mitochondrial DNA fragments and other patterns that the innate immune system reads as danger signals, even in the absence of infection.
3. Gut barrier dysfunction. The “leaky gut” concept, when it has scientific content, refers to age-related decline in intestinal epithelial integrity that allows lipopolysaccharide (LPS) and other bacterial components to enter circulation, triggering low-grade systemic inflammation.
4. Adipose tissue accumulation, particularly visceral fat. Adipose tissue is metabolically active, and visceral adipocytes secrete pro-inflammatory cytokines.
5. Immunosenescence. The aged immune system has worse pathogen control, leading to chronic subclinical infections, and altered T-cell composition that biases toward inflammatory output.

Five mechanisms, all contributing. Notice what is missing from this list: dietary inflammation in the loose sense the wellness industry uses the term, individual food sensitivities (without medically verified intolerance), and the various proprietary “inflammation panels” sold direct-to-consumer.

What CRP actually tells you

C-reactive protein (CRP) is the most commonly measured inflammation biomarker. It is a real thing. It is also less informative for personal decisions than the wellness conversation implies.

The high-sensitivity CRP (hs-CRP) test has three rough zones used in cardiovascular risk stratification: less than 1 mg/L is low risk, 1-3 mg/L is moderate, and above 3 mg/L is elevated. The number is a snapshot, not a trend. CRP rises with acute illness, recent injury, vigorous exercise in the past 48 hours, and recent vaccination. A single high reading without context tells you very little. A persistently elevated reading across multiple measurements is a real signal.

What the wellness industry does with CRP: sells you a supplement and tells you to retest in three months. What a clinician does: looks at the trend across time, considers it alongside lipid panel, fasting glucose, blood pressure, and exercise capacity, and uses it as one input among several in a cardiometabolic risk picture. The latter is more useful.

What actually reduces inflammaging

The interventions with strong evidence:

• Regular aerobic exercise. Lowers CRP, lowers IL-6, improves immune function. The effect size is meaningful and consistent across studies.
• Resistance training. Smaller effect than aerobic on inflammatory biomarkers but still measurable.
• Weight loss in adults with excess adiposity. Visceral fat reduction directly lowers inflammatory output.
• Mediterranean dietary pattern. The pattern, not the individual ingredients. Multiple large trials show CRP and other biomarker reductions.
• Adequate sleep. Sleep restriction increases inflammatory markers within days.
• Smoking cessation. Among the largest single interventions.
• Statin therapy (if indicated for cardiovascular risk). Lowers CRP independent of LDL effect.

The interventions with weaker or mixed evidence:

• Curcumin/turmeric supplements. The molecule has anti-inflammatory effects in cell culture. Bioavailability of unformulated curcumin is genuinely poor. Some formulations (BCM-95, Theracurmin, Meriva) show better human absorption. Effect on actual inflammatory biomarkers in healthy adults is small. In adults with active inflammatory conditions, larger effects.
• Omega-3 fatty acids. Modest reductions in some inflammatory markers at doses of 2-3g EPA/DHA combined daily. The evidence is real but the effect is smaller than the marketing implies.
• “Adaptogens” (ashwagandha, rhodiola, etc.). The category does have some well-controlled human studies for specific outcomes (sleep, cortisol), but the inflammation-specific evidence is patchier than the marketing.

The interventions with poor evidence (in healthy adults without specific medical indication): most “anti-inflammatory” multi-ingredient formulations, IgG food sensitivity testing as a basis for elimination diets, generic “detox” protocols, and intravenous nutrient cocktails marketed as inflammation-reducing.

The senescent-cell angle

The most interesting frontier in inflammaging research is senolytic therapy: pharmacological clearance of senescent cells. The combination of dasatinib (a kinase inhibitor) and quercetin (a flavonoid) has been studied in human pilot trials with promising biomarker shifts. Franceschi and Campisi’s 2014 Journal of Gerontology paper covered the senescence-inflammaging link.

The realistic posture on senolytics: the human evidence is early. Pilot trials are encouraging but not yet at the scale that supports broad clinical use. The compounds available outside research settings (mainly quercetin in supplement form, fisetin) are at lower doses than the trial protocols and the bioavailability picture is not as clean. This is a space worth watching, not a space worth betting protocols on yet.

Where this leaves the practical picture

For someone serious about reducing inflammaging on the basis of evidence:

1. Get a baseline hs-CRP and one or two repeat measurements over months to establish your trend.
2. Address the lifestyle inputs first. Exercise, weight, sleep, smoking, dietary pattern. The leverage is here.
3. Consider omega-3 supplementation if dietary fish is low. 2-3g EPA/DHA daily, well-tolerated.
4. Consider a high-bioavailability curcumin formulation if you want to try it. Realistic expectations on effect size.
5. Watch the senolytics literature. Do not jump in based on pilot data.
6. Be skeptical of multi-ingredient “inflammation support” formulations. The dose math rarely supports the claims.

The peptide research angle

NuroCore catalogues research compounds with mechanisms that interact with parts of the inflammaging picture. The most relevant are not anti-inflammatory in the standard sense, but they support tissue maintenance and immune regulation:

• Thymosin Alpha-1 has the cleanest immune-modulation evidence in the catalogue, with research on T-cell function in immunocompromised populations.
• BPC-157 has anti-inflammatory effects in animal models, particularly at the gut-barrier site that overlaps with the inflammaging gut-permeability story.
• MOTS-c and the broader mitochondrial-maintenance compounds address the mitochondrial-dysfunction driver of inflammaging covered in our mitochondrial health piece.

None of these is a clean “anti-inflammatory” in the way curcumin is marketed. They sit in a more specific research-context posture, addressing one mechanistic input each.

The honest takeaway

Inflammaging is real. The mechanism is multi-causal. The best interventions are lifestyle, not supplements. Most consumer “anti-inflammatory” formulations are weaker than the marketing suggests. CRP is a useful biomarker when interpreted correctly and a poor one when treated as a hero metric. Senolytics are interesting but early. The honest version of this story is less dramatic than the wellness-industry version, and more useful.

Read next

• Mitochondrial Health: Where Longevity Research Got Serious
• Autophagy and Fasting: What the Published Research Actually Supports
• Protein Synthesis After 40: Anabolic Resistance and What Actually Works

Citations

1. Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Annals of the NY Academy of Sciences. 2000;908:244-254. PMID: 10911963
2. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nature Reviews Cardiology. 2018;15(9):505-522. PMID: 30065258
3. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nature Medicine. 2019;25(12):1822-1832. PMID: 31806905
4. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. Journals of Gerontology Series A. 2014;69(Suppl 1):S4-9. PMID: 24833586